{"id":2768,"date":"2020-09-17T21:18:54","date_gmt":"2020-09-17T21:18:54","guid":{"rendered":"https:\/\/techclot.com\/index.php\/2020\/09\/17\/prevencio-develops-highly-accurate-artificial-intelligence-driven-blood-test-for-kawasaki-disease\/"},"modified":"2020-09-17T21:18:54","modified_gmt":"2020-09-17T21:18:54","slug":"prevencio-develops-highly-accurate-artificial-intelligence-driven-blood-test-for-kawasaki-disease","status":"publish","type":"post","link":"https:\/\/techclot.com\/index.php\/2020\/09\/17\/prevencio-develops-highly-accurate-artificial-intelligence-driven-blood-test-for-kawasaki-disease\/","title":{"rendered":"Prevencio Develops Highly Accurate, Artificial Intelligence-driven Blood Test for Kawasaki Disease"},"content":{"rendered":"

Prevencio Develops Highly Accurate, Artificial Intelligence-driven Blood Test for Kawasaki Disease<\/a><\/p>\n

KIRKLAND, Wash.–(BUSINESS WIRE<\/a><\/span><\/span>)–Prevencio, Inc. today announces the development of a highly accurate blood test, HART KD, for diagnosis of Kawasaki disease. The company collaborated with Seattle Children\u2019s Research Institute and leveraged its Artificial Intelligence (AI)-driven HART platform and expertise in developing cardiac blood tests.\n<\/p>\n

<\/blockquote>\n

\nKawasaki disease is a rare but fatal childhood disease that causes inflammation in the walls of arteries throughout the body. It occurs mostly in children younger than 5 years old. Previously, there were no specific tests available for diagnosis. Experts like Dr. Michael Portman from Seattle Children\u2019s Hospital believe that COVID-19 is triggering <\/b>Kawasaki disease in some cases.\n<\/p>\n

\n\u201cAmong the main presenting symptoms of Kawasaki disease are persistent fever and rash. This makes diagnosis challenging as thousands of children with these symptoms present annually to U.S. emergency departments,\u201d stated Michael Portman, MD, director of pediatric cardiovascular research at Seattle Children\u2019s and professor of pediatrics at the University of Washington School of Medicine. \u201cWith COVID-19-associated Multisystem Inflammatory Syndrome in Children (MIS-C), diagnosis of Kawasaki disease has become even more challenging and critical as the two have similar presenting symptoms, and it remains unclear whether Kawasaki disease can be triggered by the COVID virus.\u201d\n<\/p>\n

\nWithout early treatment, Kawasaki disease can cause an increased risk of coronary (heart) artery dilation and aneurysms (ballooning), leading to the need for lifelong therapy and cardiac interventions.\n<\/p>\n

\n\u201cBefore this, there was no specific diagnostic test for Kawasaki disease,\u201d Portman added. \u201cWe are excited with the robust accuracy of HART KD and appreciate our collaboration with Prevencio to address this critical, unmet medical need.\u201d\n<\/p>\n

\nPrevencio used their long-standing, certified laboratory partner, Myriad RBM, to conduct protein measurements on blood samples collected from children with Kawasaki disease and is developing commercial options for offering HART KD for children suspected of Kawasaki disease.\n<\/p>\n

\n\u201cWe are pleased to collaborate with Seattle Children\u2019s Research Institute, one of the nation\u2019s top five pediatric research centers,\u201d stated Rhonda Rhyne, Prevencio\u2019s chief executive officer. \u201cWe are excited to expand use of our AI Hart platform to Kawasaki disease and to be at the forefront of treating COVID-related medical issues. Prevencio retains world-wide exclusive rights and is exploring protein-measuring platforms and licensing partnerships to distribute HART KD.\u201d\n<\/p>\n

\nAbout Prevencio HART Tests:<\/b>\n<\/p>\n

\nPowered by Artificial Intelligence (AI), Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics. Employing this novel approach, the company has developed eight blood tests that significantly improve diagnoses for a variety of heart and blood vessel-related complications.\n<\/p>\n

\nHART Tests:\n<\/p>\n